In complement test, Creative Biolabs has advanced laboratory technology and proven testing platforms to provide customers with accurate, confidential, efficient, reliable and cost-effective autoantibody test services to meet their needs. We are committed to leveraging our expertise in autoantibody test to accelerate the progress of our clients' projects.
Background of Anti-factor B Autoantibody
Complement dysregulation caused by anti-complement autoantibodies is involved in the pathophysiology of a number of diseases. Autoantibodies against the complement regulator factor B (FB) are detected in patients with dense deposit disease (DDD), C3 glomerulonephritis (C3GN) and atypical hemolytic uremic syndrome (aHUS). Anti-FB autoantibody affects complement regulation and is implicated in the pathophysiology of these diseases. The anti-FB autoantibody can bind to FB and/or the individual component Bb part of C3 convertase. More importantly, this autoantibody can target the alternative pathway C3 convertase but has some features that distinguish it from C3NeF. The anti-FB autoantibody binds to and stabilizes the alternative pathway C3 convertase, enhancing the activity of the C3 convertase, which often leads to an increase of complement breakdown products. Upon binding, the anti-FB autoantibody stabilizes the convertase against both natural and factor H-mediated decay and thus enhances C3 consumption (Fig.1). However, the anti-FB antibody inhibits the activation of the terminal pathway, likely by interfering with the formation of the C5 convertase. Therefore, the differences between anti-FB autoantibody and C3NeF include the binding of the autoantibody to native FB in plasma and the Bb fragment of the C3 convertase, and interference with C5 convertase activity.
Fig. 1 The anti-FB autoantibody can be detected using ELISA.1
Anti-FB Autoantibody Test
The anti-FB autoantibody represents an additional acquired driver of disease in DDD, C3GN, and aHUS. Therefore, the anti-FB autoantibody test should be considered in the comprehensive evaluation of patients with these diseases. Furthermore, the anti-FB autoantibody test contributes to the diagnosis of these diseases and the development of targeted therapies. Typically, the anti-FB autoantibody test can be deleted by enzyme-linked immunosorbent assay (ELISA) with purified FB immobilized on the microtiter plate at 5 ug/ml. Serial dilutions of serum samples from patients are used as internal standards. The data obtained as the optical density value is converted into U/ml units according to the standard.
Our Services of Anti-FB Autoantibody Test
For many years, our comprehensive complement diagnostic test is powered by scientifically proven ELISA technology and designed specifically to test complement autoantibody. Our scientists have experience in developing and optimizing ELISA assays for anti-FB autoantibody. At each step, Creative Biolabs’s scientists will work in close collaboration with the customer, offering high-quality anti-FB autoantibody test service and data with highest accuracy and reproducibility. Our ELISA assay services are available for both pre-clinical and clinical trials.
Why Choose Creative Biolabs’s ELISA Test Service for Your Research?
-
Our tests are highly sensitive and specific, providing a comprehensive ELISA selection to meet your demands.
-
Our dedicated ELISA testing experts ensure that your samples are treated in full accordance with the contracted research requirements. We offer the rapid delivery of results and unparalleled testing service.
-
With our team of highly experienced scientists, we provide you with data of the highest accuracy and reproducibility.
Creative Biolabs will continue to make unremitting efforts to provide services and technology to meet customer's requirements. Please feel free to contact us for more information about our complement testing services.
Reference
1. Hauer, Jill J., et al. "Factor B and C4b2a autoantibodies in C3 glomerulopathy." Frontiers in immunology 10 (2019): 668.
Questions & Answer
A: Complement factor B is a complement protein unique to the complement-activated alternative pathway (AP). Autoantibodies targeting factor B are called anti-factor B autoantibodies. This antibody stabilizes C3 convertase and prevents its decay. It also blocks the formation of C5 convertase, thereby inhibiting the activity of the terminal pathway. And it has been found in a small number of individuals and only in patients with C3 Glomerulopathy (C3G).
A: Anti-factor B autoantibodies assay is usually performed using ELISA assays. This method primarily tests the binding of anti-factor B autoantibodies to their target complement proteins. The plate is typically coated with a full-length protein, Bb fragment or Ba fragment. After incubation with purified IgG, binding can be detected using anti-human IgG.
A: Anti-factor B autoantibodies bind to the Bb portion of the single component of factor B/C3 convertase. This enhances C3 converting enzyme activity and leads to an increase in complement breakdown products. Based on this antibody characterization, it has been found to be associated with dense deposit disease (DDD), C3 glomerulonephritis (C3GN), and atypical hemolytic uremic syndrome (aHUS). This antibody may represent an additional acquired disease driver in DDD, C3GN, and aHUS.
For Research Use Only.
Related Sections:
